Showing results (171-180 of 192) with videos related to

Sort By:
Pageof 20
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2017
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117Mikkael A Sekeres, Megan Othus, Alan F List, et al.
Blood|July 31, 2020
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotypeDavid A Sallman, Amy F McLemore, Amy L Aldrich, et al.
Biomarker Research|August 21, 2020
AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG reportEra L Pogosova-Agadjanyan, Anna Moseley, Megan Othus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2021
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic SyndromesDavid A Sallman, Amy E DeZern, Guillermo Garcia-Manero, et al.
Blood|May 14, 2008
Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDSLi Zhou, Aaron N Nguyen, Davendra Sohal, et al.
Pageof 20